Reviva Pharmaceuticals   Report issue

For profit Phase 2 Phase 3
Founded: San Jose CA United States (2006)
Status: Left NME R&D (2020)

Organization Overview

First Clinical Trial
2011
NCT01490086
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Reviva Pharmaceuticals

Active Ingredients

Drugs in Phase 3 Trials (1)

Brilaroxazine (2 trials)

Drugs in Phase 2 Trials (1)

aripiprazole (abilify) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Psychotic Disorders (Phase 2)

Schizophrenia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2